Introduction: Common risk factors for cardiovascular disease are associated with age-related cognitive decline. The Brief Memory and Executive Test (BMET) is a clinical screening tool, which is sensitive and specific to Vascular Cognitive Impairment (VCI), an impairment characterised by decline in frontally-mediated cognitive functions (e.g. executive function and processing speed). Method: Our aim was to cross-sectionally assess the validity of the BMET as a measure of the subclinical effects of vascular risk on cognition, in an otherwise healthy elderly cohort. Data from 346 participants (57 ± 10 years) without major neurological or psychiatric disorders were included in this study, gathered as part of a previous multicentre validation study for the BMET. Framingham Vascular Age was used as a surrogate measure of vascular risk, incorporating several established risk factors. Univariate General Linear models were used to relate Vascular Age to performance on Executive Function/Processing Speed and Memory subtests of the BMET, adjusting for Age, Premorbid Intelligence and Ethnicity. Results: Adverse vascular risk was associated with poorer performance on both the Memory and Executive Function/Processing Speed indices, adjusted for age, premorbid intelligence and ethnicity (p = 0.011 and p < 0.001, respectively). Discussion: Performance on the BMET reflects the subclinical effects of vascular risk on cognition in age-related cognitive decline. Vascular risk is associated with decline in both executive function/processing speed and memory groups of subtests. Future studies are needed to explore whether treating vascular risk factors can effectively reduce age-related cognitive decline.
Hippocampus volume, cognition and stroke: Data from the Stem cell Trial of recovery EnhanceMent after Stroke 2 (STEMS-2)
Kiruparan N 1 , Dineen R 1 , Auer D 1 , Bath P 1 , Abaei M 1 , England T 2 1 Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK 2 Division of Health Sciences and GEM, University of Nottingham, Nottingham, UK Introduction: Granulocyte-colony stimulating factor (G-CSF) improves outcome in experimental stroke. Mobilised CD34 + cells might enhance recovery by neurorepair. The hippocampus is damaged as a result of stroke and may adversely affect cognition. The aims of the study were to determine the relationship between G-CSF, hippocampal volume (HV) and cognition. Methods: STEMS-2, a randomised placebo-controlled trial, administered G-CSF (10 μg/kg) or placebo (2:1) subcutaneously for 5 days to 60 patients 3-30 days post stroke. Normalised HV change (ΔHV) was measured using MRI (Day 0, Day 90) in an optional substudy, in addition to baseline stroke severity (National Institutes of Health Stroke Scale, NIHSS Day 0) and Mini-Mental State Examination (MMSE, Day 90). Statistical significance was taken at p < 0.05. Results: 18 paired scans were analysed, 12 G-CSF, 6 placebo. Reasons for no scan included: patient refusal (n = 17), contraindication (n = 4), scan intolerance (n = 1), severe illness (n = 5), poor quality (n = 6), not indi-cated (n = 9 haemorrhages). Of the 18, mean age 73.4 (7.5) and 55.6% female, there was a significant decrease in ipsilateral HV (paired t-test, p = 0.001) and contralateral HV (p = 0.004). Ipsilateral ΔHV and day 90 MMSE score were correlated (Pearson Correlation, r = −0.48, p = 0.049). No statistical difference was found between G-CSF and placebo groups in ipsilateral or contralateral ΔHV. There was no significant correlation between stroke lesion volume (or NIHSS) and ΔHV. Discussion: HV significantly decreases 3 months after stroke and correlates with a low MMSE score, independent of stroke lesion size and severity. G-CSF did not significantly influence HV in this small sample.
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The Geriatric Anxiety Inventory (GAI): A good option to screen for anxiety in older people after stroke?
